Literature DB >> 15885081

The expression of human leukocyte antigen-DR and CD25 on circulating T cells in cutaneous lupus erythematosus and correlation with disease activity.

Joerg Wenzel1, Stephanie Henze, Sabine Brähler, Thomas Bieber, Thomas Tüting.   

Abstract

BACKGROUND: Lupus erythematosus (LE) is a chronic autoimmune disease with a broad clinical spectrum reaching from primarily cutaneous manifestations [cutaneous LE (CLE)] up to systemic disease [systemic LE (SLE)]. In patients with SLE, the expression of activation markers on circulating T cells reflects disease activity. Here, we investigated whether this also holds true for patients with CLE. PATIENTS AND METHODS: The expression of the activation markers human leukocyte antigen (HLA)-DR and CD25 on circulating T lymphocytes was measured by flow cytometry in 24 patients suffering from different types of active CLE. Simultaneously, the disease activity was assessed clinically using a CLE activity index. Eighteen healthy donors were analyzed for control purposes.
RESULTS: HLA-DR was expressed on a significantly elevated percentage of both CD4+ and CD8+ circulating T cells in active CLE patients when compared with healthy controls. The percentage of HLA-DR-expressing T lymphocytes closely correlated with the disease activity. Interestingly, in disseminated scarring chronic discoid LE, a significantly increased percentage of CD25+ cells was observed only in the subset of skin-homing cutaneous lymphocyte antigen (CLA)+CD4+ and CD8+ T cells.
CONCLUSION: Our results provide evidence that activation markers on peripheral blood T cells might help to objectively assess the disease activity in CLE. Furthermore, a significant population of CD25+CLA+CD8+ T cells can only be detected in a subgroup of patients with disseminated scarring CLE and might reflect the systemic expansion of activated cytotoxic T lymphocytes involved in destruction of epidermal tissue.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15885081     DOI: 10.1111/j.0906-6705.2005.00301.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  11 in total

Review 1.  The pathogenesis of primary cicatricial alopecias.

Authors:  Matthew J Harries; Ralf Paus
Journal:  Am J Pathol       Date:  2010-10-01       Impact factor: 4.307

Review 2.  The beneficial role of vitamin D in systemic lupus erythematosus (SLE).

Authors:  Khanh vinh quốc Luong; Lan Thi Hoàng Nguyễn
Journal:  Clin Rheumatol       Date:  2012-07-17       Impact factor: 2.980

3.  Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo.

Authors:  Nicole L Regna; Cristen B Chafin; Sarah E Hammond; Abdul G Puthiyaveetil; David L Caudell; Christopher M Reilly
Journal:  Clin Immunol       Date:  2014-01-15       Impact factor: 3.969

4.  HLA association in SLE patients from Lahore-Pakistan.

Authors:  Nageen Hussain; Ghazala Jaffery; Anjum Nasim Sabri; Shahida Hasnain
Journal:  Bosn J Basic Med Sci       Date:  2011-02       Impact factor: 3.363

5.  Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare.

Authors:  Inbal Braunstein; Noah G Goodman; Misha Rosenbach; Joyce Okawa; Asha Shah; Michael Krathen; Carrie L Kovarik; Eline Luning Prak; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2011-08-06       Impact factor: 11.527

6.  Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients.

Authors:  Siamak Moghadam-Kia; Katherine Chilek; Elizabeth Gaines; Melissa Costner; Mathew E Rose; Joyce Okawa; Victoria P Werth
Journal:  Arch Dermatol       Date:  2009-03

Review 7.  Dendritic cells and the immunopathogenesis of systemic lupus erythematosus.

Authors:  Seetha Monrad; Mariana J Kaplan
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

8.  Role of P-glycoprotein on CD69+CD4+ cells in the pathogenesis of proliferative lupus nephritis and non-responsiveness to immunosuppressive therapy.

Authors:  Shizuyo Tsujimura; Tomoko Adachi; Kazuyoshi Saito; Yoshiya Tanaka
Journal:  RMD Open       Date:  2017-07-14

Review 9.  Current Insights in Cutaneous Lupus Erythematosus Immunopathogenesis.

Authors:  Colton J Garelli; Maggi Ahmed Refat; Padma P Nanaware; Zaida G Ramirez-Ortiz; Mehdi Rashighi; Jillian M Richmond
Journal:  Front Immunol       Date:  2020-07-02       Impact factor: 7.561

10.  T Cell Dysregulation in Non-silicotic Silica Exposed Workers: A Step Toward Immune Tolerance Breakdown.

Authors:  Benoit Brilland; Céline Beauvillain; Gery Mazurkiewicz; Pierre Rucay; Yves Roquelaure; Julie Tabiasco; Emeline Vinatier; Jérémie Riou; Pascale Jeannin; Gilles Renier; Jean-François Subra; Jean-François Augusto
Journal:  Front Immunol       Date:  2019-11-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.